Patrick Y. Wen, MD

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss potential directions for future research in primary central nervous system malignancies.

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss ongoing research to watch in primary central nervous system tumors.

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss available data for plixorafenib in central nervous system tumors harboring BRAF V600 mutations from the FORTE trial.

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss the safety profile and management of toxicities associated with BRAF inhibitors in central nervous system tumors.

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss the novel BRAF inhibitor plixorafenib and its ongoing evaluation in central nervous system malignancies.

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss the use of BRAF inhibitors in the treatment of patients with central nervous system malignanices.

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss current treatment approaches in central nervous system malignancies.

Dr Wen discussed the significance of the FDA approval of dordaviprone for patients at least 1 year of age with H3K27M-mutated diffuse midline glioma.

Patrick Y. Wen, MD, discusses the evaluation of vorasidenib in IDH1- and IDH2-mutated low-grade glioma, as evaluated in the phase 3 INDIGO trial.

Patrick Y. Wen, MD, discusses the efficacy of the pan-RAF inhibitor tovorafenib in children and young adults with low-grade glioma and highlights the importance of continual clinical research in this disease.